Navigation Links
Replicon in Medical News

ImQuest BioSciences and Arisyn Therapeutics Introduce Novel New HCV Therapeutic Agent at Hepatitis Conference

... its potential mechanism of antiviral action through the selection of a replicon resistant to the antiviral effects of the compound. Resistant HCV replicon sequences were selected in cell culture and resulted in mutations in the ...

Study Showing Improved Virologic Response with Nitazoxanide in Chronic Hepatitis C Published in Gastroenterology

... as a treatment of chronic hepatitis C. Nitazoxanide is a potent inhibitor of hepatitis C virus (HCV) replication in HCV genotype 1-derived replicon cell lines, and in vitro studies have shown that it does not induce mutations in the virus that confer resistance. Phase II clinical trials are ...

Tibotec presents interim findings for TMC435, an investigational genotype 1 hepatitis C treatment

... parameters, ECGs, or vital signs. Steady-state plasma trough levels of TMC435 25 mg and 75 mg represented ~10 and >30-fold excess above the HCV replicon EC50 value, respectively. Mean reductions of HCV RNA from baseline to day seven with TMC435 alone and in triple therapy were 2.63 and 3.47 log10 ...

Morphine Withdrawal Complicates Hepatitis C Infection in Drug Abusers

... events that occur in liver cells. Although the replicon does not produce the infectious virus, the HCV replicon system represents the best available system for ... that there was an increase in the number of HCV replicon in both the withdrawal scenario. Furthermore, ...

Link Between Hepatitis C And Liver Cancer Unraveled By Scientists

... cancer. Reduced quantities of the protein product of the retinoblastoma gene have been found in cells that harbor the Hepatitis C ‘replicon’. A replicon is nothing but a part of the genetic material of the hepatitis C virus that has the intrinsic property of self-replication and protein production. ...
Replicon in Medical Technology

Romark Announces Presentation of New Data for Nitazoxanide in Chronic Hepatitis C at EASL 2008

... genotypes, predominately genotype 4. replicon studies and an early clinical experience ... Nitazoxanide or Tizoxanide in HCV-Containing replicon Cell Lines," also demonstrated that treatment of HCV replicon cells with tizoxanide potentiates the ...

Anadys Pharmaceuticals Presents Data on ANA598, a Non-Nucleoside Inhibitor of the HCV Polymerase, at the 21st International Conference on Antiviral Research

... ANA598 retained full activity against a number of replicon mutations known to confer resistance to ... of the protein-binding adjusted genotype 1a replicon EC95, suggesting the potential for twice-daily or ... inhibitor, cellular activity in the hepatitis C replicon assay, oral bioavailability and early indicators ...

XTL Biopharmaceuticals Presents Data Regarding its Hepatitis C Virus Small Molecule Program at Hep Dart 2007 - an International Scientific Conference on Viral Hepatitis

... Potency of these compounds was evaluated in a replicon assay, which is known to have good correlation ... clinical testing of inhibitors of HCV. In the replicon assay, the compounds had single-digit nM ... to be significantly more potent than A831 in the replicon assay. A second poster presentation entitled ...

Idenix Pharmaceuticals Presents Positive Preclinical Data on HCV Programs at The Annual Meeting of The European Association for the Study of the Liver (EASL)

... activity of the drug and limiting systemic side effects. In an HCV replicon model, IDX184 exhibited 10 times greater potency than the first-generation ... IDX184 demonstrated additive antiviral activity in the HCV replicon in combination with HCV protease inhibitors and interferon and ...

Anadys Pharmaceuticals Announces Positive Results for ANA598 in Animal Model of Chronic Hepatitis C Virus Infection

... including intrinsic potency as an NS5B inhibitor, cellular activity in the replicon assay, oral bioavailability and early indicators of safety and ... concentrations of ANA598 exceeded the EC95 for HCV genotype 1a and 1b replicon inhibition. The EC95 is the concentration required in vitro to suppress ...

AlphaVax Announces Results From Phase 1 Influenza Vaccine Clinical Trial

... trial in 216 volunteers of an influenza vaccine based on its proprietary replicon vector platform. This study was designed to further assess the properties ... vaccine for colon cancer. Additional clinical trials of AlphaVax replicon vaccines for infectious disease, biodefense, and cancer indications are ...

AlphaVax Announces Promising Results in Melanoma Studies

... Annual Meeting in Seattle, Washington. Results from pre-clinical studies conducted at MSKCC demonstrate the ability of AlphaVax's virus-like replicon vector particles (VRP) encoding melanoma-specific tumor antigens to reduce melanoma tumor burden in a state-of-the-art murine melanoma model. ...

Tibotec Presents Interim Findings for TMC435, an Investigational Genotype 1 Hepatitis C Treatment, at the AASLD Liver Meeting 2008

... parameters, ECGs, or vital signs. Steady-state plasma trough levels of TMC435 25 mg and 75 mg represented ~10 and >30-fold excess above the HCV replicon EC50 value, respectively. Mean reductions of HCV RNA from baseline to day seven with TMC435 alone and in triple therapy were 2.63 and 3.47 log10 ...

Idenix Pharmaceuticals Advances HCV Discovery Program to Clinic

... that IDX375 targets the palm non-nucleoside pocket of HCV polymerase. IDX375 has exhibited single nanomolar in vitro potency against HCV genotype 1b replicon (EC50 = 2 nM) and against HCV genotype 1a and 1b polymerases. Additionally, cellular cytotoxicity testing in Huh-7 cells demonstrated that IDX375 is ...

Idenix Pharmaceuticals Reports First Quarter 2008 Financial Results

... preclinical data from its HCV protease inhibitor program, with internally discovered compounds exhibiting potency in the HCV replicon system and good pharmacokinetic profiles in several animal species. "We have made significant progress in the last six months in ...
Replicon in Biological News

Evolutionary origin of bacterial chromosomes revealed

... I and III, Agrobacteria gene movements have produced second chromosomes derived from plasmids, while in the biovar II strain K84 the plasmid-based replicon has yet to reach second chromosome status." Derek Wood, associate professor at Seattle Pacific University, remarked: "The findings in this work ...

Hepatitis C complicated by morphine withdrawal

... withdrawal enhances hepatitis C virus (HCV) replicon expression, appears in the November issue of The ... measure HCV replication, they used a virus-like replicon that mimics the events that occur in liver cells ... RNA and proteins that HCV uses. Although the replicon does not produce the infectious virus, the ...

Cyclosporine inhibits hepatitis C virus in vitro

... on hepatitis C in vitro. For the in vitro study, the researchers, led by Roberto J. Firpi, M.D. of the University of Florida, treated the HCV replicon line, GSB1, with varying doses of Cyclosporine for 48 hours and examined the results. They found that Cyclosporine reduced HCV replication by 20 ...

Texas scientists discover how a hepatitis C protein promotes liver cancer

... hepatitis C genetic material that is able to reproduce itself in cultured cells and also able to produce proteins made by hepatitis C viruses. "The replicon experiments enabled us to identify a protein known as NS5B that attaches to the retinoblastoma protein, a critical tumor suppressor, and accelerates ...

A comprehensive response to HIV could prevent 10 million AIDS deaths in Africa by 2020

... the researchers inserted the gene for the HER2/neu protein in place of the deleted viral genes and then packaged the virus vector into virus-like replicon particles, referred to as “VRP-neu.?When these non-propagating particles are injected into an animal, the vector directs the animal’s cells to make ...

Gene Vaccine Protects Mice Against Development Of Her2/neu Breast Cancer

... the researchers inserted the gene for the HER2/neu protein in place of the deleted viral genes and then packaged the virus vector into virus-like replicon particles, referred to as “VRP-neu.?When these non-propagating particles are injected into an animal, the vector directs the animal’s cells to make ...

More>>

Replicon in Biological Technology

GenOdyssee Receives Broad Product Applications Protection in EU for Founding Natural Evolution Technology

... efficacy using the industry gold standard replicon assay without significantly increased toxicity as ... in vitro in the HCV genotype 1b subgenomic replicon assay (BM4-5 cells) as compared to IFN alpha 2. ... alpha 2. - Viral clearance of HCV genotype 1b replicon subgenome was obtained in BM4-5 cells after ...

InterMune to Present Four Abstracts on HCV Protease Inhibitor ITMN-191 at the AASLD Meeting

... assays. One assay modeled HCV replication (14-day replicon clearance assay) and the other assay modeled ... in significantly enhanced clearance of the HCV replicon and reduced or suppressed the emergence of ... of the NS5B Inhibitors R1626 or R7128 Enhances replicon Clearance and Reduces the Emergence of Drug ...

InterMune Reports Third Quarter 2008 Financial Results and Business Highlights

... moiety of polymerase inhibitor R7128 (Roche/Pharmasset) in a 14-day replicon clearance assay and in a 3-week colony formation assay resulted in clearance of the HCV replicon and reduced or suppressed the emergence of drug-resistant viral ...

InterMune to Present Abstracts on HCV Protease Inhibitor ITMN-191 and HCV Development Program at the EASL Meeting

... follows: Combination of the NS3/4A Protease Inhibitor ITMN-191 with the Allosteric NS5B Polymerase Inhibitor ITMN-8020 Enhances replicon Clearance and Reduces the Emergence of Drug Resistant Variants . Discovery of Potent, Bioavailable HCV NS3/4A Inhibitors that Display ...

Romark and Chugai Pharmaceutical Enter Into Exclusive Licensing Agreement for Nitazoxanide in Japan

... as a treatment of chronic hepatitis C. Nitazoxanide is a potent inhibitor of hepatitis C virus (HCV) replication in HCV genotype 1-derived replicon cell lines, and in vitro studies have shown that it does not induce mutations in the virus that confer resistance. In phase II clinical trials, the ...

Romark Announces Presentation of New Data for Controlled Release Nitazoxanide in Chronic Hepatitis C

... as a treatment of chronic hepatitis C. Nitazoxanide is a potent inhibitor of hepatitis C virus (HCV) replication in HCV genotype 1-derived replicon cell lines, and in vitro studies have shown that it does not induce mutations in the virus that confer resistance. In phase II clinical trials, the ...

Anadys Pharmaceuticals Reports First Quarter 2008 Financial Results and Highlights

... interferon-alpha and non-antagonistic with ribavirin in cell-based assays. ANA598 was also shown to retain full activity against a number of replicon mutations known to confer resistance to other anti-HCV agents currently in clinical development, including protease inhibitors and nucleoside ...

XTL Biopharmaceuticals Signs $108 Million Deal for the Licensing of its Pre- Clinical Program in Hepatitis C to Presidio Pharmaceuticals

... production. NS5A is distinct from the protease and polymerase. The Program's lead compounds are highly potent inhibitors of viral replication in the replicon assay, which is known to have good correlation with clinical efficacy and is currently the leading method for preclinical testing of inhibitors of ...

Your Data: Silencing Hepatitis C Virus Replication With In Vitro Transcribed siRNAs

... multiple siRNAs targeting various regions of the HCV subgenomic replicon sequence. These siRNAs were transfected into an Huh-7 cell line that stably expressed the HCV RNA replicon and screened for their gene silencing activities by real-time ...
Replicon in Biological Dictionary

Replicon

... A replicon is a DNA molecule or RNA molecule, or a region ... from a single origin of replication. A replicon in genetics is a region of DNA or RNA, that replicates from a single ... replicon is a software company providing timesheet and ...

More>>

Other Contents
(Date:12/19/2014)... December 20, 2014 Sweetdressy.com , ... has introduced its newest selection of cheap prom dresses ... very popular in the world and clients can buy ... Meanwhile, these prom dresses feature cool cuts and delicate ... now, targeting the middle-end market. Discount shipping costs are ...
(Date:12/19/2014)... December 19, 2014 SuperCloset raises the ... Rooms. SuperCloset continues to offer indoor growers the most ... of the new SuperClone Rooms with the award winning ... turnkey indoor hydroponic grow room setup. , The SuperClone ... SuperCloset’s SuperPonic SuperCloner 50 . The ...
(Date:12/19/2014)... The print component of Vision and Hearing is distributed ... Star, with a circulation of approximately 230,433 copies and ... distributed nationally through a vast social media strategy and ... outlets. To explore the digital version of the campaign, ... an exclusive interview with Mark DeMontis , sharing his ...
(Date:12/19/2014)... drug users who also use cocaine and amphetamines have ... users, a new study finds. "We know that ... attempt and completed suicide," Didier Jutras-Aswad, a psychiatry professor ... news release. "However, there are many different profiles of ... users were actually more likely to attempt suicide." ...
(Date:12/19/2014)... Diet Doc strives to continue to ... weight loss by combining scientific fast weight ... the company understand that remaining committed to a diet ... carbohydrates and sugars from the diet can cause patients ... weight loss goals. , For this reason, Diet ...
Breaking Medicine News(10 mins):Health News:Cheap Prom Dresses Online Now at Sweetdressy.com 2Health News:SuperCloset Continues to Innovate with New Complete Indoor Grow Room Packages, The SuperClone Rooms are the Newest Addition to the Award Winning SuperRoom Lineup 2Health News:Mark DeMontis, Founder of Courage Canada, shares his passion for bringing hockey to those affected by blindness in Mediaplanet’s “Vision and Hearing” campaign 2Health News:Cocaine, Amphetamines May Up Injection Drug Users' Suicide Risk 2Health News:Diet Doc Incorporates Appetite Zap into their Already Impressive Collection of Diet Products to Jump Start the Metabolism and Burn Fat 4X Faster 2Health News:Diet Doc Incorporates Appetite Zap into their Already Impressive Collection of Diet Products to Jump Start the Metabolism and Burn Fat 4X Faster 3Health News:Diet Doc Incorporates Appetite Zap into their Already Impressive Collection of Diet Products to Jump Start the Metabolism and Burn Fat 4X Faster 4
(Date:12/17/2014)... NEW YORK , Dec. 15, 2014 /PRNewswire-USNewswire/ ... a Good Clinical Practices (GCP) audit to confirm ... Administration (FDA) regulations. This accomplishment enables HITLAB to ... trials utilizing the highest principles for patient safety ... to improve global healthcare access, quality, and delivery ...
(Date:12/15/2014)... Research and Markets ( http://www.researchandmarkets.com/research/87pph8/global_facial ... "Global Facial Recognition Market 2015-2019" report to ... Facial recognition is a technology ... system measures the overall facial feature of a ... the distance between eyes. Facial recognition is used ...
(Date:12/11/2014)... 10, 2014  Data Sciences International (DSI), the ... a new series of digital telemetry implants to ... M series, part of the PhysioTel™ Digital platform, ... possible physiologic data when incorporating functional endpoints into ... to toxicology studies has evolved from short ECG ...
Breaking Biology News(10 mins):HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3New telemetry implants expected to change how large animal toxicology studies are conducted 2
Other TagsOther Tags